CN103796648B - 用γ-醛酮清除剂治疗炎症和高血压的方法 - Google Patents
用γ-醛酮清除剂治疗炎症和高血压的方法 Download PDFInfo
- Publication number
- CN103796648B CN103796648B CN201280044440.6A CN201280044440A CN103796648B CN 103796648 B CN103796648 B CN 103796648B CN 201280044440 A CN201280044440 A CN 201280044440A CN 103796648 B CN103796648 B CN 103796648B
- Authority
- CN
- China
- Prior art keywords
- inflammatory
- inflammation
- compounds
- acid
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910951171.5A CN111494352A (zh) | 2011-07-12 | 2012-07-12 | 用γ-醛酮清除剂治疗炎症和高血压的方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506848P | 2011-07-12 | 2011-07-12 | |
| US61/506,848 | 2011-07-12 | ||
| PCT/US2012/046549 WO2013010034A2 (en) | 2011-07-12 | 2012-07-12 | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910951171.5A Division CN111494352A (zh) | 2011-07-12 | 2012-07-12 | 用γ-醛酮清除剂治疗炎症和高血压的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103796648A CN103796648A (zh) | 2014-05-14 |
| CN103796648B true CN103796648B (zh) | 2019-10-25 |
Family
ID=47506934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280044440.6A Active CN103796648B (zh) | 2011-07-12 | 2012-07-12 | 用γ-醛酮清除剂治疗炎症和高血压的方法 |
| CN201910951171.5A Pending CN111494352A (zh) | 2011-07-12 | 2012-07-12 | 用γ-醛酮清除剂治疗炎症和高血压的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910951171.5A Pending CN111494352A (zh) | 2011-07-12 | 2012-07-12 | 用γ-醛酮清除剂治疗炎症和高血压的方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10975033B2 (enExample) |
| EP (1) | EP2731597B1 (enExample) |
| JP (1) | JP6280033B2 (enExample) |
| KR (2) | KR20140050661A (enExample) |
| CN (2) | CN103796648B (enExample) |
| AU (1) | AU2012281061B2 (enExample) |
| BR (1) | BR112014000810A8 (enExample) |
| CA (1) | CA2844150C (enExample) |
| ES (1) | ES2970814T3 (enExample) |
| HU (1) | HUE065757T2 (enExample) |
| MX (1) | MX383365B (enExample) |
| PL (1) | PL2731597T3 (enExample) |
| WO (1) | WO2013010034A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130018478A (ko) * | 2011-08-09 | 2013-02-25 | 주식회사 엘지화학 | 신규한 구조의 이차전지 팩 |
| US10166248B1 (en) * | 2015-12-21 | 2019-01-01 | Vanderbilt University | Methods of preventing platelet activation |
| US11400103B2 (en) * | 2015-12-21 | 2022-08-02 | Vanderbilt University | Methods of preventing platelet activation |
| CA3030036A1 (en) * | 2016-07-06 | 2018-01-11 | Vanderbilt University | Use of scavengers of reactive gamma-ketoaldehydes to extend cell lifespan and healthspan |
| PL3481505T3 (pl) * | 2016-07-07 | 2026-01-26 | Vanderbilt University | Zapobieganie i leczenie migotania/trzepotania przedsionków za pomocą środków wychwytujących gamma-ketoaldehyd |
| EP3510014B8 (en) * | 2016-09-06 | 2026-07-29 | MTI Biotech, Inc. | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nash or ald |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| EP4385576A3 (en) * | 2016-11-15 | 2024-09-04 | Vanderbilt University | Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension |
| HUE066390T2 (hu) | 2017-04-27 | 2024-07-28 | Univ Vanderbilt | Eljárások ateroszklerózis kezelésére gamma-ketoaldehid-szkevendzserekkel |
| US20210023032A1 (en) | 2017-09-05 | 2021-01-28 | Mti Biotech, Inc. | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
| WO2019050967A1 (en) * | 2017-09-05 | 2019-03-14 | Metabolic Technologies, Inc. | COMPOSITIONS AND METHODS OF USING GAMMA-KETOALDEHYDE SENSORS TO TREAT, PREVENT, OR IMPROVE LIVER FIBROSIS |
| CN109836341B (zh) * | 2017-11-28 | 2021-08-27 | 江阴技源药业有限公司 | 一种水杨胺醋酸盐的制备方法 |
| US20200197323A1 (en) * | 2018-12-21 | 2020-06-25 | Vanderbilt University | Methods for suppressing accumulation of reflux-induced protein adducts |
| US20230069820A9 (en) * | 2019-09-24 | 2023-03-02 | Vanderbilt University | Use of 2-hydroxybenzylamine for the treatment of systemic lupus |
| WO2021154877A1 (en) * | 2020-01-27 | 2021-08-05 | Vanderbilt University | Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof |
| CN118652245B (zh) * | 2024-08-21 | 2024-11-12 | 首都医科大学附属北京儿童医院 | 一种化合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002036109A2 (en) * | 2000-11-02 | 2002-05-10 | University Of South Carolina | Use of pyridoxamine for the treatment and inhibition of obesity-related complications |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740439A (en) * | 1968-06-24 | 1973-06-19 | Ciba Geigy Corp | Treating hypertension with beta-aminoalkane carboxylic acids |
| US3794734A (en) | 1971-03-03 | 1974-02-26 | Merck & Co Inc | Methods of treating edema and hypertension using certain 2-aminoethylphenols |
| US4123537A (en) * | 1977-05-26 | 1978-10-31 | Merck & Co., Inc. | 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema |
| US8178516B2 (en) * | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
| US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| AU5659796A (en) | 1995-05-19 | 1996-11-29 | Kissei Pharmaceutical Co. Ltd. | 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors |
| US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
| US6824786B2 (en) * | 2001-11-27 | 2004-11-30 | Ruey J. Yu | Compositions comprising phenyl-glycine derivatives |
| US7705054B1 (en) * | 2004-10-20 | 2010-04-27 | Vanderbilt University | Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases |
| EP2207555B1 (en) * | 2007-10-05 | 2013-07-24 | InDex Pharmaceuticals AB | Oligonucleotides for the treatment or alleviation of edema |
| KR100973343B1 (ko) * | 2008-02-01 | 2010-07-30 | 롯데칠성음료주식회사 | 기호성이 우수한 혼합차 조성물 및 그 제조방법 |
| CN101305759B (zh) * | 2008-06-19 | 2011-09-07 | 成都大学 | 一种苦荞保健茶及其制备方法 |
| CN101843671A (zh) * | 2009-03-25 | 2010-09-29 | 王文祥 | 苦荞托毒丸及其制备方法 |
| EP2477594A4 (en) * | 2009-07-15 | 2013-03-13 | Univ Vanderbilt | ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY |
| CN101606986A (zh) * | 2009-07-29 | 2009-12-23 | 李钢 | 一种具有降糖作用的组合物及其药物 |
-
2012
- 2012-07-12 US US14/232,615 patent/US10975033B2/en active Active
- 2012-07-12 CA CA2844150A patent/CA2844150C/en active Active
- 2012-07-12 BR BR112014000810A patent/BR112014000810A8/pt not_active Application Discontinuation
- 2012-07-12 JP JP2014520341A patent/JP6280033B2/ja active Active
- 2012-07-12 WO PCT/US2012/046549 patent/WO2013010034A2/en not_active Ceased
- 2012-07-12 ES ES12811030T patent/ES2970814T3/es active Active
- 2012-07-12 CN CN201280044440.6A patent/CN103796648B/zh active Active
- 2012-07-12 MX MX2014000515A patent/MX383365B/es unknown
- 2012-07-12 AU AU2012281061A patent/AU2012281061B2/en active Active
- 2012-07-12 EP EP12811030.1A patent/EP2731597B1/en active Active
- 2012-07-12 HU HUE12811030A patent/HUE065757T2/hu unknown
- 2012-07-12 KR KR1020147003650A patent/KR20140050661A/ko not_active Ceased
- 2012-07-12 PL PL12811030.1T patent/PL2731597T3/pl unknown
- 2012-07-12 KR KR1020197016572A patent/KR102050700B1/ko active Active
- 2012-07-12 CN CN201910951171.5A patent/CN111494352A/zh active Pending
-
2021
- 2021-04-13 US US17/229,593 patent/US20210261508A1/en not_active Abandoned
-
2024
- 2024-10-16 US US18/917,759 patent/US20250034093A1/en active Pending
- 2024-10-16 US US18/917,789 patent/US20250214939A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002036109A2 (en) * | 2000-11-02 | 2002-05-10 | University Of South Carolina | Use of pyridoxamine for the treatment and inhibition of obesity-related complications |
Non-Patent Citations (1)
| Title |
|---|
| Sean S. Davies 等.Pyridoxamine Analogues Scavenge Lipid-Derived ç-Ketoaldehydes and Protectagainst H2O2-Mediated Cytotoxicity.《Biochemistry》.2006,第45卷第15756-15767页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2844150C (en) | 2019-09-03 |
| BR112014000810A2 (pt) | 2017-06-13 |
| JP2014524918A (ja) | 2014-09-25 |
| MX383365B (es) | 2025-03-13 |
| EP2731597A2 (en) | 2014-05-21 |
| US10975033B2 (en) | 2021-04-13 |
| AU2012281061A1 (en) | 2014-02-20 |
| PL2731597T3 (pl) | 2024-04-29 |
| MX2014000515A (es) | 2014-03-27 |
| US20250034093A1 (en) | 2025-01-30 |
| ES2970814T3 (es) | 2024-05-30 |
| US20140256774A1 (en) | 2014-09-11 |
| KR20140050661A (ko) | 2014-04-29 |
| AU2012281061B2 (en) | 2017-08-03 |
| KR102050700B1 (ko) | 2019-11-29 |
| CN103796648A (zh) | 2014-05-14 |
| WO2013010034A3 (en) | 2013-03-28 |
| HUE065757T2 (hu) | 2024-06-28 |
| BR112014000810A8 (pt) | 2022-11-29 |
| WO2013010034A2 (en) | 2013-01-17 |
| EP2731597B1 (en) | 2023-12-20 |
| CA2844150A1 (en) | 2013-01-17 |
| KR20190069607A (ko) | 2019-06-19 |
| JP6280033B2 (ja) | 2018-02-14 |
| CN111494352A (zh) | 2020-08-07 |
| EP2731597C0 (en) | 2023-12-20 |
| US20250214939A1 (en) | 2025-07-03 |
| EP2731597A4 (en) | 2015-04-08 |
| US20210261508A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034093A1 (en) | Method for treating lupus with gamma-ketoaldehyde skavengers | |
| JP6929425B2 (ja) | ピペリジニルインドール誘導体の新規な使用 | |
| Lin et al. | Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer’s Disease | |
| JP6499077B2 (ja) | アルツハイマー病と関連疾患の治療のための併用療法 | |
| JP2011518874A (ja) | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン | |
| JP6027607B2 (ja) | プテロスチルベンの抗不安効果 | |
| Ji et al. | Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau. P301S mouse model of Alzheimer’s disease and frontotemporal dementia | |
| US12060379B2 (en) | Plasmalogen derivatives | |
| Verma et al. | Chronic anatabine treatment reduces Alzheimer’s disease (AD)-like pathology and improves socio-behavioral deficits in a transgenic mouse model of AD | |
| US9603869B2 (en) | Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders | |
| Small | Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer’s disease: do we need new inhibitors? | |
| US8541435B2 (en) | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD) | |
| JP2017119722A (ja) | タウ凝集阻害剤 | |
| JP7295145B2 (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
| TW201038265A (en) | Agent for treatment of cognitive impairment | |
| HK40023703A (en) | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers | |
| HK1191859B (en) | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers | |
| HK1191859A (en) | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers | |
| CN116157118A (zh) | 2-hoba治疗动脉粥样硬化的用途 | |
| JP2017530943A (ja) | Ｔｌｒ非依存性低分子アジュバント | |
| RU2712229C2 (ru) | Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора | |
| Tan et al. | Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders | |
| JP2025177416A (ja) | タンパク質の凝集抑制剤 | |
| KR20150013122A (ko) | 염증을 치료하고 면역 반응을 조절하기 위한 화합물 및 이의 용도 | |
| Roberts II | Opening lecture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: ROBERTS L. JACKSON Inventor after: AMARNATH VENKATARAMAN Inventor after: HARRISON DAVID G. Inventor after: L Jackson Roberts Amaernate Venkataraman, David G Harrison Annette clapper Inventor before: ROBERTS L. JACKSON Inventor before: AMARNATH VENKATARAMAN Inventor before: HARRISON DAVID G. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |